National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, human epidermal growth factor receptor 2 -negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.


NCPE Assessment Process Complete
Rapid review commissioned 22/07/2020
Rapid review completed 03/09/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of alpelisib (Piqray®) compared with the current standard of care.